References Chapter 3


  1. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis. 2005 Mar.21;3(5):288–96.

  2. Steingart KR, Henry M, Ng V, Hopewell PC. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:570–81.

  3. Toman's Tuberculosis: Case Detection Treatment, and Monitoring: Questions and Answers. 2nd ed. Frieden TR, editor. World Health Organization, Geneva; 2004.

  4. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007May;11(5):485–95.

  5. Ramsay A, Yassin MA, Cambanis A, Hirao S, Almotawa A, Gammo M, et al. Front-Loading Sputum Microscopy Services: An Opportunity to Optimise Smear-Based Case Detection of Tuberculosis in High Prevalence Countries. J Trop Med. 2009;2009:1–6.

  6. Laboratory services in tuberculosis control Part II: microscopy. World Health Organization, Geneva. 1998 (WHO/TB/98.258).
    http://www.ghdonline.org/drtb/discussion/laboratory-services-in-tuberculosis-controlmicr-2/

  7. Bonnet M, Ramsay A, Githui W, Gagnidze L, Varaine F, Guerin PJ. Bleach Sedimentation: An Opportunity to Optimize Smear Microscopy for Tuberculosis Diagnosis in Settings of High Prevalence of HIV. Clin Infect Dis. 2008 Jun.;46(11):1710–6.

  8. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005 Mar.1;25(3):564–9.

  9. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva. (WHO/HTM/TB/2008.392).
    http://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/index.htm

  10. Rapid implementation of the Xpert MTB/RIF diagnostic test. World Health Organization, Geneva. (WHO/HTM/TB/2011.2).
    http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf

  11. Prerequisites to country implementation of Xpert MTB/RIF and key action points at country level. World Health Organization, Geneva. (WHO/HTM/TB/2011.12).
    http://whqlibdoc.who.int/hq/2011/WHO_HTM_TB_2011.12_eng.pdf

  12. Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. World Health Organization, Geneva. (WHO/HTM/TB/2011.4).
    http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf

  13. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. Elsevier Ltd; 2011 Apr.30;377(9776):1495–505.

  14. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: A meta-analysis. J Infect. Elsevier Ltd; 2012 Jun.1;64(6):580–8.
    http://tbevidence.org/wp-content/uploads/2012/04/Chang-J-Infect-2012.pdf

  15. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med. 2010 Sep.9; 363(11):1005–15.
    http://www.nejm.org/doi/abs/10.1056/NEJMoa0907847

  16. World Health Organization. The use of Xpert MTB/RIF assay for the detection of pulmonary and extrapulomnary tuberculosis and rifampicin resistance in adults and children. Expert group meeting. October 2013.
    http://www.stoptb.org/wg/gli/assets/documents/Xpert%20Meeting%20Report%2024102013%20%20Pre%20publication%20FINAL.pdf

  17. Mironova S, Pimkina E, Kontsevaya I, Nikolayevskyy V, Balabanova Y, Skenders G, Kummik T, Drobniewski F. Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1381-7. Epub 2011 Oct.25.

  18. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. J Clin Microbiol. 2007 Aug.3;45(8):2635–40.

  19. Wei-Lun Huang, Ting-Lin Chi, Mei-Hua Wu, Ruwen Jou. Performance Assessment of the GenoType MTBDRsl Test and DNA Sequencing for Detection of Second-Line and Ethambutol Drug Resistance among Patients Infected with Multidrug-Resistant Mycobacterium tuberculosis. J Clin Microbiol. 2011 July; 49(7): 2502–2508. doi: 10.1128/JCM.00197-11.

  20. Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother. Am Soc Microbiol; 1997 Sep.19;41(10):2093–8.

  21. Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsai YC. Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis 7(6):569-574.

  22. UNTAID Secretariat. Tuberculosis Diagnositc Technology Landscape 2012. UNTAID Secretariat, World Health Organization, Geneva, Switzerland. 2012.
    http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-Tuberculosis-Landscape_2012.pdf

  23. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. World Health Organization. Geneva, Switzerland 2001 (WHO/HTM/TB/2011.6).
    http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf

  24. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care 2006.
    http://www.who.int/tb/publications/2006/istc/en/index.html

  25. Tshibwabwa-Tumba E, Mwinga A, Pobee J, Zumla A. Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three Central African Hospitals. Clin Radiol. Elsevier; 2012 Aug.17;52(11):837–41.

  26. Burrill J, Williams CJ, Bain G, Conder G, Hine AL, Misra RR. Tuberculosis: A Radiologic Review. Radiographics. 2007 Sep.1;27(5):1255–73.

  27. Gryminski J, Krakowka P, Lypacewicz G. The diagnosis of pleural effusion by ultrasonic and radiologic techniques. Chest. 1976.

  28. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis. 1993 Dec.;17(6):968–75.

  29. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-[gamma] release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. Elsevier Ltd; 2011 Dec.11; 12(1):45–55.

  30. Use of tuberculosis interferon-gamma release assays (IGRAs) in low–and middle income countries: policy statement. World Health Organization, Geneva. 2011.
    http://whqlibdoc.who.int/publications/2011/9789241502672_eng.pdf

  31. Runyon BA, Montano AA, Akriviadis EA. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Annals of Internal Medicine; 1992. p. 215-20.

  32. Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):289-94.

  33. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009 Sep.;23(14):1875–80.

  34. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012 Nov;40(5):1211-20. doi: 10.1183/09031936.00201711. Epub 2012 Feb 23.

  35. Stephen D Lawn Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infectious Diseases 2012, 12:103. doi:10.1186/1471-2334-12-103.